Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9476Neoplasms 6587Prostatic Neoplasms 4399Colorectal Neoplasms 3977Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Pancreatic Neoplasms 2478Carcinoma, Hepatocellular 2411Leukemia, Myeloid, Acute 2265Multiple Myeloma 2120Stomach Neoplasms 2108Neoplasm Metastasis 1911Head and Neck Neoplasms 1869Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1729Brain Neoplasms 1699Rectal Neoplasms 1676Melanoma 1654Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1485Esophageal Neoplasms 1311Glioblastoma 1307Lymphoma, Non-Hodgkin 1204Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × BRCA1 Mutation × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

NCT05420064 2025-11-12

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Memorial Sloan Kettering Cancer Center

Phase NA Recruiting
1,000 enrolled

BRCA1 Mutation

NCT01630226 2012-07-12

Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland

Pomeranian Medical University Szczecin

Phase 2 Unknown
100 enrolled
Breast

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡